IGC Pharma Inc. (IGC)
NYSE: IGCHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IGC stock chart
Technical analysisKey statistics
All statistics- Market cap
- $19.60M
- EPS (TTM)
- -$0.07
- Dividend yield
- None
- 52-week range
- 0.08 – 0.36
- Day range
- 0.168 – 0.1863
- Volume / Avg
- 500.33K / 615.25K
- Beta
- —
- Shares outstanding
- 116.69M
52-week range
IGC stock today
On Nov 20, IGC ended the session at $0.168, shedding $0.016 (8.70%), versus the S&P 500's 3.70% decline. Shares are 53.3% below their 52-week high of $0.36, set on Dec 10, 2025 and 110.0% above the 52-week low of $0.08, in the middle of the past year's range. IGC is down 40.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 47.5%.
IGC Pharma has posted a net loss over the last twelve months (EPS of -$0.07), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About IGC Pharma
Company profileIGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Ram Mukunda
- Headquarters
- Potomac, MD
- Employees
- 70
- Website
- igcpharma.com
Financial highlights
Full financialsIn fiscal 2025, IGC Pharma generated $1.3 million in revenue, down 5.5% from fiscal 2024, its first annual decline since 2022. IGC Pharma reported a net loss of $7.1 million, compared with a loss of $13.0 million a year earlier. Gross margin was 48.7% (down from 54.5%) and operating margin -585.8%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $1.27M | $1.34M | $911.00K | $397.00K | $898.00K |
| Growth | -5.50% | +47.64% | +129.47% | -55.79% | -77.95% |
| Net income | $-7.12M | $-13.00M | $-11.51M | $-15.02M | $-8.81M |
| EPS (diluted) | $-0.09 | $-0.22 | — | — | $-0.21 |
Analyst forecast
ForecastConsensus (1 analysts)
none
Avg. price target
$6.00+3471.43%
- Strong buy 0
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 13, 2026
- EPS actual vs est.
- $-0.02 vs $-0.02
- Surprise
- 0.00%
IGC Pharma peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TXMDTherapeuticsMD Inc. | 1.71 | -5.52% | $19.79M | vs IGC |
| ACETAdicet Bio Inc. | 2.14 | -13.01% | $20.03M | vs IGC |
| RNAZTransCode Therapeutics Inc. | 1.16 | -10.77% | $20.07M | vs IGC |
| AARDAardvark Therapeutics Inc. | 0.9226 | -7.74% | $20.20M | vs IGC |
| CPHIChina Pharma Holdings Inc. | 0.4384 | -13.00% | $18.86M | vs IGC |
| COCPCocrystal Pharma Inc. | 0.95 | -2.05% | $18.30M | vs IGC |
| MRKRMarker Therapeutics Inc. | 1.09 | -17.42% | $18.17M | vs IGC |
| KTTAPasithea Therapeutics Corp. | 0.4787 | -0.48% | $17.59M | vs IGC |
Indexes, lists and sector
IGC Pharma stock FAQ
What is IGC Pharma's stock price today?
IGC last traded at $0.168 as of Nov 20, 4:00 PM EST, down 8.70% on the day. Prices are delayed at least 15 minutes.
Does IGC Pharma pay a dividend?
No. IGC Pharma does not currently pay a regular cash dividend.
Who is IGC Pharma's CEO?
Mr. Ram Mukunda is the chief executive officer of IGC Pharma Inc., which has about 70 employees.
Has IGC ever split its stock?
Yes. The most recent IGC stock split was a 1-for-10 split on Apr 19, 2013.
What is the IGC 52-week high?
The 52-week high for IGC is $0.36 and the 52-week low is $0.08. The stock is currently 53.3% below its high.